{
    "2019-05-17": [
        [
            {
                "time": "2023-10-18",
                "original_text": "Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL",
                "features": {
                    "keywords": [
                        "FDA",
                        "Venclexta",
                        "Gazyva",
                        "CLL",
                        "approval"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "AbbVie halts enrollment after brain cancer trial misses goal, shares fall",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "trial failure",
                        "brain cancer",
                        "shares fall"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "AbbVie stock down 1.8% in premarket trade after failure of glioblastoma drug trial",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "stock down",
                        "premarket",
                        "glioblastoma",
                        "drug trial"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Depatuxizumab Mafodotin",
                        "glioblastoma",
                        "update"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs",
                "features": {
                    "keywords": [
                        "FDA",
                        "LLY",
                        "PFE",
                        "ABBV",
                        "cancer drugs",
                        "approval"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}